Active Not Recruiting OBSERVATIONAL NCT06226896

Effects of Dapagliflozin on Progression of Alport Syndrome

Sponsor: Nanjing University School of Medicine

Updated 5 times since 2024 Last updated: Sep 1, 2024 Started: Nov 15, 2023 Primary completion: Jun 30, 2026 Completion: Sep 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Alport Syndrome and is currently ongoing. Nanjing University School of Medicine leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Oct 2024 — Present [monthly]

Active Not Recruiting
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting
Feb 2024 — Jul 2024 [monthly]

Recruiting

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing University School of Medicine

Data source: Nanjing University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China